Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Purchases 37,595 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero bought 37,595 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were purchased at an average price of $1.32 per share, for a total transaction of $49,625.40. Following the completion of the purchase, the director directly owned 773,296 shares of the company’s stock, valued at approximately $1,020,750.72. This trade represents a 5.11% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero bought 46,620 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $1.35 per share, for a total transaction of $62,937.00.
• On Thursday, August 27th, Ramiro Guerrero acquired 78,239 shares of MAIA Biotechnology stock. The shares were bought at an average price of $1.39 per share, with a total value of $108,752.21.
• On Wednesday, August 26th, Ramiro Guerrero acquired 8,931 shares of MAIA Biotechnology stock. The shares were purchased at an average cost of $1.39 per share, for a total transaction of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero purchased 1,794 shares of MAIA Biotechnology stock. The shares were purchased at an average price of $1.33 per share, for a total transaction of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero acquired 11,899 shares of MAIA Biotechnology stock. The stock was purchased at an average price of $1.37 per share, with a total value of $16,301.63.

MAIA Biotechnology Price Performance

Shares of MAIA traded up $0.06 during mid-day trading on Monday, reaching $1.35. 122,008 shares of the company’s stock were exchanged, compared to its average volume of 775,572. The business’s fifty day simple moving average is $1.35 and its 200-day simple moving average is $1.39. The stock has a market capitalization of $82.42 million, a PE ratio of -2.19 and a beta of 0.25. MAIA Biotechnology, Inc. has a 52-week low of $0.87 and a 52-week high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities research analysts predict that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current year.

Institutional Investors Weigh In On MAIA Biotechnology

Large investors have recently modified their holdings of the stock. Susquehanna International Group LLP acquired a new position in MAIA Biotechnology in the 2nd quarter valued at $51,000. Cable Car Capital LP acquired a new position in MAIA Biotechnology during the 2nd quarter worth approximately $741,000. BlackRock Inc. purchased a new position in shares of MAIA Biotechnology during the 2nd quarter worth approximately $580,000. Centric Wealth Management acquired a new stake in shares of MAIA Biotechnology in the 2nd quarter valued at approximately $1,107,000. Finally, PVG Asset Management Corp purchased a new stake in shares of MAIA Biotechnology in the first quarter valued at approximately $46,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.